Compare GNT & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GNT | MDXH |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.5M | 149.0M |
| IPO Year | N/A | 2021 |
| Metric | GNT | MDXH |
|---|---|---|
| Price | $8.86 | $2.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 65.6K | ★ 254.9K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 6.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | $9.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.87 | $1.67 |
| 52 Week High | $9.30 | $5.33 |
| Indicator | GNT | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 56.95 | 40.67 |
| Support Level | $7.76 | $1.93 |
| Resistance Level | $9.30 | $2.75 |
| Average True Range (ATR) | 0.19 | 0.18 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 63.27 | 80.54 |
GAMCO Natural Resources, Gold & Income Trust is a non-diversified closed-end management investment company. The company's primary investment objective is to provide a high level of current income from interest, dividends, and options premiums with its secondary objective being capital appreciation. Under normal market conditions, the company invests majority of its assets in securities of companies principally engaged in the natural resources and gold industries, and also engages in writing covered call options on the underlying equity securities. Its portfolio consists of securities from different sectors such as metals and mining, energy and energy services, specialty chemicals, agriculture, healthcare, machinery, food and beverage, and others.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.